MAY 25, 2020 6:07 AM PDT

FDA Approves the First Treatment for Neurofibromatosis 1

WRITTEN BY: Carmen Leitch

In a major breakthrough, the Food and Drug Administration (FDA) has approved a treatment for a genetic disorder called neurofibromatosis type one (NF1). The disease impacts more than 2.5 million people and can cause a type of tumor growth on nerves called plexiform neurofibromas, which can be debilitating and painful. The drug, Koselugo (selumetinib) is the first treatment for NF1, and is intended for use in patients who have been tested for the disease at the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH).

Clinical trials that assessed the efficacy of the drug showed that in more than 70 percent of patients with inoperable plexiform neurofibromas, Koselugo reduced tumor size by 20 to 60 percent. There was a visual reduction in tumor size, and pain was lessened in patients, who also reported greater mobility, better physical function, and improved quality of life.

The drug is an MEK inhibitor; it targets a biochemical signaling pathway in cells called Ras/Raf/MEK/ERK, which is involved in the survival and growth of cells. MEK inhibitors have been studied as potential cancer therapeutics, and it was found that they could dramatically affect the size of NF1 tumors. The first encouraging results were reported by Dr. Brigitte Widemann at a 2015 NF Conference. Additional confirmatory studies have followed.  

On a personal note, I'm thrilled to learn of this development, though it's bittersweet. My mother had NF1 and died several years ago. It's heartening, however, to hear that patients have been updated throughout the course of these clinical trials. Science and medicine have come a long way since my mother's diagnosis, when very little was known about the disease, and she was diagnosed and quickly dismissed from a doctor's office. While the hereditary nature of NF was known in the medical community by 1900, diagnostic criteria weren't set by the NIH until 1988, and the NF1 gene was not identified until 1990. By 2019, patients were being included in the FDA's first 'NF listening session.'

There are other MEK inhibitors in clinical trials now (like mirdametinib by SpringWorks Therapeutics), so patients might have more treatment options in the near future.

Image credit: Public Domain Pictures / George Hodan

"We are so excited for the entire NF community today! This announcement from the FDA about Koselugo (selumetinib) is a tremendous step towards our ultimate dream - approved treatments for all forms of neurofibromatosis," said Annette Bakker, PhD, President of the Children's Tumor Foundation. "We believe that FDA approval of this treatment helps not only a subset of NF1 patients, it opens the door to increased interest in all forms of NF by pharmaceutical companies. We are already experiencing it; the number of companies interested in NF1, NF2, and schwannomatosis is growing rapidly."

Sources: AAAS/Eurekalert! via Children's Tumor Foundation, FDA

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAR 30, 2020
Microbiology
MAR 30, 2020
The Microbial Communities That Form on the Tongue
Scientists used a fluorescent imaging tool to analyze how bacteria grow on the human tongue.
APR 01, 2020
Genetics & Genomics
APR 01, 2020
Using Modified Stem Cells, Researchers Make Old Mice Youthful Again
Scientists were able to make old human cells revert to a younger state by activating the expression of a few genes at ce ...
APR 19, 2020
Genetics & Genomics
APR 19, 2020
Two New Viruses IDed in Brazilian Patient Samples
After an assessment of blood samples collected in Brazil between 2013 and 2016, scientists have found two new species of ...
MAY 20, 2020
Genetics & Genomics
MAY 20, 2020
Native Americans Have an Ancient Connection to Lake Baikal
People have lived around Lake Baikal, the world's deepest and oldest lake, for thousands of years.
JUN 10, 2020
Genetics & Genomics
JUN 10, 2020
Our Genes Influence How Sensitive We Are
Maybe you've been told that you are too sensitive, or you know someone who has strong reactions to positive, negative, o ...
JUN 15, 2020
Cell & Molecular Biology
JUN 15, 2020
Revealing the Network of Neurons in the Heart
The autonomic nervous system is linked to the intrinsic cardiac nervous system (ICN), which is thought to help regulate ...
Loading Comments...